NCT07686042 Efficacy and Safety of Low-Dose Blinatumomab in the Treatment of Refractory Autoimmune Encephalitis and Autoimmune Cerebellitis Status NOT_YET_RECRUITING Phase PHASE4
NCT07643103 Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospective Umbrella Trial Status NOT_YET_RECRUITING Phase PHASE2
NCT07636564 Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment Status NOT_YET_RECRUITING Phase PHASE2
NCT07604233 Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML Status NOT_YET_RECRUITING Phase PHASE1/PHASE2
NCT07573670 A Phase 2 Study of Bcl-2 Inhibitor Combined With Azacitidine for Newly Diagnosed Mixed Phenotype Acute Leukemia Status NOT_YET_RECRUITING Phase PHASE2
NCT07570173 A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005) Status RECRUITING Phase PHASE2/PHASE3
NCT07564453 Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia Status RECRUITING Phase PHASE2
NCT07495631 Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia Status RECRUITING Phase NA
NCT07493161 Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL Status RECRUITING Phase NA
NCT07476729 International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) Status NOT_YET_RECRUITING Phase PHASE3
NCT07454226 ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL Status RECRUITING Phase NA
NCT07387926 Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL) Status RECRUITING Phase PHASE1/PHASE2
NCT07297914 Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL Status NOT_YET_RECRUITING Phase PHASE2/PHASE3
NCT07294677 CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL Status RECRUITING Phase PHASE1/PHASE2
NCT07283640 A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia Status NOT_YET_RECRUITING Phase PHASE1
NCT07223190 A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia Status NOT_YET_RECRUITING Phase PHASE3
NCT07192237 Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia Status NOT_YET_RECRUITING Phase PHASE2
NCT07178912 Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Status NOT_YET_RECRUITING Phase PHASE2
NCT07153796 A Phase 1b/2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2